With 100 million people dealing with obesity, previous treatments relied on injections. While these injections worked well, many people didn't use them because of a dislike for needles and the high cost. Now, the FDA has approved an oral version of Wegovy from Novo Nordisk, which is the first of its kind.

The US now has an approved oral weight loss medication, marking a big change in how obesity is treated.

I. Dosage form breakthrough: unlocking convenience in treatment

The oral Wegovy doesn't require injections; you just take it on an empty stomach and wait 30 minutes. This gets rid of any concerns about needles. Plus, it works just as well as the injectable form, with people in studies losing an average of 13.6% of their body weight. The same good results, but in a pill, means more people will stick with their treatment. This starts a new phase where weight loss treatment is much easier to manage.

II. Affordable prices: lower the threshold for medication

Before, injected GLP-1 drugs cost over $1,000 a month, which was too much for most people. The oral Wegovy will start at just $149 a month, and it's cheaper to make. Experts believe that if the price drops to $300-$500, a lot more people will be able to afford it. This could open up a market with millions of new patients.

III. Three, Pattern Reshaping: The Balance Race between Efficacy and Convenience

III. Three, Pattern Reshaping: The Balance Race between Efficacy and Convenience

Competition is heating up, giving patients more options. Besides Novo Nordisk's oral pill, Eli Lilly is also releasing an oral weight loss drug soon. Their injectable drug, Zepbound, helps people lose even more weight, averaging 21%. The key in this competition is finding the right mix of affordability, good results, and ease of use. This will make weight loss treatments available to more people, creating more fairness in healthcare.